CN111000249A - Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof - Google Patents
Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN111000249A CN111000249A CN201911197176.XA CN201911197176A CN111000249A CN 111000249 A CN111000249 A CN 111000249A CN 201911197176 A CN201911197176 A CN 201911197176A CN 111000249 A CN111000249 A CN 111000249A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- oral liquid
- weight
- compound plant
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 102
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 93
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 92
- 239000007788 liquid Substances 0.000 title claims abstract description 30
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims abstract description 30
- 244000068988 Glycine max Species 0.000 claims abstract description 26
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 24
- 244000302512 Momordica charantia Species 0.000 claims abstract description 20
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 20
- 240000006162 Chenopodium quinoa Species 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 230000001603 reducing effect Effects 0.000 claims abstract description 9
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 7
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 3
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 241000756042 Polygonatum Species 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000037831 Polygonatum sibiricum Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 3
- 235000018365 Momordica dioica Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000037063 Thinness Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010048828 underweight Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000018648 unbalanced nutrition Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound plant polypeptide oral liquid for losing weight and reducing blood sugar and a preparation method thereof; the raw materials comprise main materials, auxiliary materials and purified water; every 100 milliliters of the compound plant polypeptide oral liquid comprises 1 to 10 grams of quinoa polypeptide, 0.1 to 0.5 gram of bitter gourd polypeptide, 1 to 5 grams of micromolecule soybean polypeptide and auxiliary materials, wherein the auxiliary materials mainly comprise: the health-care food is obtained by dissolving 0.5-1 g of polygonatum sibiricum extract, 0.1-0.2 g of momordica grosvenori extract and 1-5 g of L-arabinose in water.
Description
Technical Field
The invention relates to a compound plant polypeptide oral liquid for losing weight and reducing blood sugar and a preparation method thereof.
Background
In recent years, diabetes has become one of 3 chronic non-infectious diseases threatening human health worldwide. The fifth edition of the international diabetes union states that diabetes has become a major killer of current threats to human health. The research in 2002 finds that the prevalence rate of urban diabetes in China is about 4.5 percent; a survey of diabetes mellitus for more than 9 million people aged 18 years in 31 province and city in 2010 shows that the rate of diabetic patients is as high as 9.65%. Along with the improvement of living standard, the increase of nutrient intake and the acceleration of working rhythm of people, the prevalence rate of diabetes rises year by year, and the development trend is not optimistic.
Disclosure of Invention
Aiming at the defects of the prior art, the invention solves the problems that: provides a weight-losing and sugar-reducing compound plant polypeptide oral liquid with the functions of small intestine digestion and absorption, auxiliary regulation of blood fat, blood sugar and blood pressure, fatigue relief, liver protection and organism immunity improvement and a preparation method thereof.
In order to solve the problems, the technical scheme adopted by the invention is as follows:
a compound plant polypeptide oral liquid for reducing weight and lowering blood sugar is prepared from main material, adjuvant and purified water; every 100 milliliters of the compound plant polypeptide oral liquid comprises 1 to 10 grams of quinoa polypeptide, 0.1 to 0.5 gram of bitter gourd polypeptide, 1 to 5 grams of micromolecule soybean polypeptide and auxiliary materials, wherein the auxiliary materials mainly comprise: 0.5-1 g of polygonatum extract, 0.1-0.2 g of momordica grosvenori extract and 1-5 g of L-arabinose.
Furthermore, the main materials of the compound plant polypeptide oral liquid per 100 ml comprise 8 g of quinoa polypeptide, 0.2g of balsam pear polypeptide and 2g of micromolecular soybean polypeptide.
Furthermore, the auxiliary materials in each 100 ml of the compound plant polypeptide oral liquid comprise 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 3.5g of L-arabinose.
Furthermore, the quinoa polypeptide, the momordica charantia polypeptide and the small molecular soybean polypeptide are small molecular peptides with the molecular weight of below 2000.
Furthermore, the molecular weight of the small-molecular soybean polypeptide is 180-2000.
Furthermore, the molecular weight of the small-molecular soybean polypeptide is 180-1000.
Furthermore, the molecular weight of the small-molecular soybean polypeptide is 250-1000.
A preparation method of a compound plant polypeptide oral liquid for losing weight and reducing blood sugar comprises the following steps:
s1, mixing the main materials according to the mixture ratio of the components, and then adding purified water to dissolve;
s2, adding auxiliary materials into the main materials dissolved in the step S1 for dissolving;
s3, performing damp-heat sterilization on the solution of the main material and the auxiliary material in the step S2 to obtain the compound plant polypeptide oral liquid.
The invention has the advantages of
1. Compared with the prior art, the invention takes a plurality of plant active polypeptides as nitrogen sources, is easy to be absorbed in the small intestine, is beneficial to the quick and efficient utilization of the organism, can effectively improve the negative nitrogen balance of the organism, and the food-borne polypeptides can improve the structure and the function of epithelial cells of the intestinal mucosa and improve the absorption capacity of the intestinal mucosa.
2. The compound plant polypeptide oral liquid is rich in various amino acids and polypeptides, has high bioavailability, is easy to be absorbed by human bodies, and can effectively improve the health states of patients with obesity, hyperglycemia, hyperlipidemia and the like; is helpful for regulating sub-health state of organism, such as improving sleep, coordinating intestine and stomach, regulating immunity, enhancing resistance, etc.; the health-care food can promote muscle recovery and protein synthesis after operation, improve protein balance, accelerate postoperative rehabilitation, increase glycogen synthesis and other effects, can be used as a formula food with special medical application for sub-health people, operation patients, tumor patients and the like, meets the special nutritional requirements of the patients, improves the nutritional status of the patients, promotes the overall health level of the patients, and provides a good basis for the treatment and recovery of diseases.
Detailed Description
The present invention will be described in further detail below.
Example 1
Weighing 8 g of quinoa polypeptide, 0.2g of bitter gourd polypeptide and 2g of micromolecular soybean polypeptide respectively, mixing uniformly, adding purified water for dissolving, adding 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 3.5g of L-arabinose for preparing 100 mL solution, subpackaging, and carrying out moist heat sterilization to obtain the compound plant polypeptide oral liquid.
Example 2
Weighing 4 g of quinoa polypeptide, 0.2g of bitter gourd polypeptide and 0.5g of micromolecular soybean polypeptide respectively, mixing uniformly, adding purified water for dissolving, adding 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 0.5g of L-arabinose for preparing 100 mL solution, subpackaging, and carrying out damp-heat sterilization to obtain the compound plant polypeptide oral liquid.
Example 3
Weighing 1g of quinoa polypeptide, 0.1 g of bitter gourd polypeptide and 2g of micromolecular soybean polypeptide respectively, mixing uniformly, adding purified water for dissolving, adding 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 0.5g of L-arabinose for preparing 100 mL solution, subpackaging, and carrying out moist heat sterilization to obtain the compound plant polypeptide oral liquid.
Example 4
Weighing 1g of quinoa polypeptide, 0.05 g of bitter gourd polypeptide and 0.5g of micromolecular soybean polypeptide respectively, mixing uniformly, adding purified water for dissolving, adding 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 0.5g of L-arabinose for preparing 100 mL solution, subpackaging, and carrying out damp-heat sterilization to obtain the compound plant polypeptide oral liquid.
Comparative example 1
The procedure is as in example 1 except that quinoa polypeptide is not contained.
Comparative example 2
The same procedure as in example 1 was followed, except that Momordica charantia polypeptide was not included.
Comparative example 3
The procedure is as in example 1 except that the soybean polypeptide is not included.
Comparative example 4
The same procedure as in example 1 was repeated, except that quinoa polypeptide, momordica charantia polypeptide and small soybean polypeptide were not included.
Experimental example 1 Effect of different compositions on weight loss
The invention observes 50 obese cases, the effective rate is 95 percent, wherein: over a month, 91% of these were lost, accounting for 5-7 kg. The weight-losing effect of the invention is remarkable, no toxic or side effect exists during taking, the invention proves that the invention can be taken for a long time, the satiety after taking is generally reflected during taking is good, the fat and protein metabolism in the body is adjusted and consumed, the toxin is rapidly decomposed to be discharged, the toxin expelling and beautifying effects are achieved, meanwhile, the nutrition supplement is comprehensive, the invention adopts a unique formula and an advanced technology, the taking is convenient, the absorption is rapid, and the rebound is avoided after the weight-losing.
The clinical curative effect is summarized as follows:
1. case selection
The invention takes the cases of severe obesity, moderate obesity and mild obesity as the selection standard: according to the calculation method recommended by the world health organization, the standard weight of a male is calculated by multiplying 70 percent by cm-80, the standard weight of a female is calculated by multiplying 60 percent by cm-70, the plus or minus 10 percent of the standard weight is the normal weight, the plus or minus 10 to 20 percent of the standard weight is overweight or underweight, and the plus or minus 20 percent of the standard weight is obese or underweight. By taking the weight as the standard, selecting the mild obesity when the weight exceeds the standard weight by 20-30%, the moderate obesity when the weight exceeds the standard weight by 30-40%, and the severe obesity when the weight exceeds the standard weight by more than 40%. A total of 60 observations were made for mildly 20, moderately obese 20, and severely obese 20.
2. Determination of therapeutic effect
The effect is shown: the body weight is reduced by more than 5 kg per month.
The method has the following advantages: the body weight is reduced by 1-4.9 kg per month.
And (4) invalidation: body weight was not reduced.
3. Method of treatment
The method is suitable for people: people with excessive weight due to unbalanced nutrition.
The taking method comprises the following steps: 50ml is taken 30 minutes before three meals each day. The dosage of the composition is doubled for patients with overweight standard weight above 40%.
Note that: reduced appetite is a normal phenomenon during administration; after the product is taken, warm and plain boiled water or mineral water is needed to be drunk more because the excessive fat in the body is consumed and toxin is decomposed.
4. Clinical results
Table 1 shows the effect of different compositions on weight loss.
TABLE 1
As can be seen from the above table, the weight-reducing effect of example 1 is the best, and the blood sugar-reducing effect of example 4 is relatively poor due to the low content of quinoa polypeptide, momordica charantia polypeptide and small-molecule soybean polypeptide. The quinoa polypeptide, the momordica charantia peptide and the small molecular soybean polypeptide are respectively lacked in the comparative example 1, the comparative example 2 and the comparative example 3, the weight-losing effect is obviously reduced, and the curative effect is also obviously reduced after the three plant polypeptides are removed in the comparative example 4. Therefore, the weight-reducing plant polypeptide composition provided by the invention has a remarkable weight-reducing effect, and all components play a role in a synergistic manner, so that a good weight-reducing curative effect is realized.
Experimental example 2 hypoglycemic Activity of different polypeptide compositions
2.1 test specimens
Examples 1 to 4, comparative examples 1 to 4.
2.2 Experimental animals
Healthy SD mice (clean grade), male and female halves, body weight (25g-40 g).
2.3 establishment and grouping of diabetic mouse models
Taking 150 mice, each half of the mice is male and female, randomly selecting 10 mice as a blank control group, feeding the rest mice with high-sugar and high-fat feed for one week, injecting a freshly prepared alloxan solution 65mg/kg through tail veins, measuring fasting blood sugar of the mice fasted for 12 hours by using a blood sugar kit after the third day, selecting the mice with the blood sugar higher than 11mmol/l as experimental objects, randomly selecting qualified mice, dividing the mice into 9 groups, and setting a diabetes model group, wherein the groups are shown in examples 1 to 4 and the groups in comparative examples 1 to 4.
2.4 blood sugar lowering experiment method
The blank control group and the model group were gavaged with physiological saline of the same volume as the former, examples 1 to 4 and comparative examples 1 to 4 at a dose of 10mg/kg, respectively, and fasting blood glucose values were measured at weeks 2, 4 and 6, respectively, for 6 consecutive weeks.
2.5 statistical methods
Each index is expressed as x + -s, and the significant difference between means is measured by t-test.
2.6 analysis of hypoglycemic action of oral liquid
Table 2 effect of different compositions on blood glucose in mice.
TABLE 2
Note: the representation of different letters in each column has significant difference (P < 0.05).
As can be seen from the above table, the blood sugar of the mice in the blank group does not change significantly after gastric lavage, and the blood sugar of the model group is significantly different from that of the blank control group (P < 0.05), which indicates that the model is successfully established, and the blood sugar of each group in examples 1-4 and comparative examples 1-4 is significantly different from that of the model group (P < 0.05), wherein the blood sugar reducing effect of example 1 is the best, and the blood sugar reducing effect of example 4 is relatively poor due to the low content of quinoa polypeptide, momordica charantia polypeptide and small-molecule soybean polypeptide. The quinoa polypeptide, the momordica charantia peptide and the small molecular soybean polypeptide are respectively absent in the comparative example 1, the comparative example 2 and the comparative example 3, the blood sugar reducing effect is obviously reduced, and the curative effect is also obviously reduced after the three plant polypeptides are removed in the comparative example 4. Therefore, the hypoglycemic drug composition provided by the invention has a remarkable hypoglycemic effect, and all components play a synergistic role, so that a good hypoglycemic curative effect is realized.
The quinoa polypeptide has a plurality of biological effects beneficial to health, can reduce low-density lipoprotein of triglyceride, promote cholesterol excretion, prevent and treat diabetes, and is beneficial to reducing the occurrence of vascular complications of diabetes; can relax bowels and guide excretion, and is helpful for patients with habitual constipation. The balsam pear polypeptide is a bioactive substance extracted from balsam pear, has obvious hypoglycemic effect, and is a natural health product. Indian scientists found that polypeptide-P in Momordica charantia has a stronger action than the hypoglycemic drug Shenfonylurea, and reported by Indian doctor Hanna, a polypeptide drug extracted from Momordica charantia was used for treating diabetes, and was as effective as insulin. The soybean polypeptide contains peptide segments such as antihypertensive peptide, cholesterol-lowering peptide, antitumor peptide, CPPS and the like, so that the soybean polypeptide can be used in the pharmaceutical industry to produce medicines with corresponding effects, such as antihypertensive drug, powerful calcium supplement, tumor inhibitor and the like which can treat both symptoms and root causes. However, in the pharmaceutical industry, the soybean peptide mixture obtained by the enzymatic hydrolysis or microbial decomposition method must be separated and purified to achieve the desired effect at a smaller dosage, and although the processing cost is increased, the additional value of the drug is also greatly increased. The vegetable protein peptide not only can rapidly provide protein nutrition, but also can improve the digestion and absorption functions of the small intestine, assist in regulating blood fat, blood sugar and blood pressure, relieve fatigue, protect the liver, improve the immunity of the organism and the like.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (8)
1. The compound plant polypeptide oral liquid for losing weight and reducing blood sugar is characterized in that the raw materials comprise main materials, auxiliary materials and purified water; every 100 milliliters of the compound plant polypeptide oral liquid comprises 1 to 10 grams of quinoa polypeptide, 0.1 to 0.5 gram of bitter gourd polypeptide, 1 to 5 grams of micromolecule soybean polypeptide and auxiliary materials, wherein the auxiliary materials mainly comprise: 0.5-1 g of polygonatum extract, 0.1-0.2 g of momordica grosvenori extract and 1-5 g of L-arabinose.
2. The oral liquid of claim 1, wherein the main ingredients of each 100 ml of the oral liquid comprise quinoa polypeptide 8 g, Momordica charantia polypeptide 0.2g, and small-molecule soybean polypeptide 2 g.
3. The weight-reducing and sugar-reducing compound plant polypeptide oral liquid as claimed in claim 1, wherein the auxiliary materials in each 100 ml of the compound plant polypeptide oral liquid comprise 1g of rhizoma polygonati extract, 0.15 g of fructus momordicae extract and 3.5g of L-arabinose.
4. The weight-reducing and sugar-reducing compound plant polypeptide oral liquid as claimed in claim 1, wherein the small molecular soybean polypeptide is a small molecular peptide with a molecular weight below 2000.
5. The weight-reducing and sugar-reducing compound plant polypeptide oral liquid as claimed in claim 4, wherein the molecular weight of the small molecular soybean polypeptide is 180-2000.
6. The weight-reducing and sugar-reducing compound plant polypeptide oral liquid as claimed in claim 4, wherein the molecular weight of the small molecular soybean polypeptide is 180-1000.
7. The weight-reducing and sugar-reducing compound plant polypeptide oral liquid as claimed in claim 4, wherein the molecular weight of the small molecular soybean polypeptide is 250-1000.
8. The preparation method of the weight-losing and sugar-reducing compound plant polypeptide oral liquid according to any one of claims 1 to 7 is characterized by comprising the following steps:
s1, mixing the main materials according to the mixture ratio of the components, and then adding purified water to dissolve;
s2, adding auxiliary materials into the main materials dissolved in the step S1 for dissolving;
s3, performing damp-heat sterilization on the solution of the main material and the auxiliary material in the step S2 to obtain the compound plant polypeptide oral liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911197176.XA CN111000249A (en) | 2019-11-29 | 2019-11-29 | Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911197176.XA CN111000249A (en) | 2019-11-29 | 2019-11-29 | Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111000249A true CN111000249A (en) | 2020-04-14 |
Family
ID=70113528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911197176.XA Pending CN111000249A (en) | 2019-11-29 | 2019-11-29 | Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111000249A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106912960A (en) * | 2017-03-06 | 2017-07-04 | 青岛海大华旗生物科技有限公司 | A kind of hypoglycemia healthcare food and preparation method thereof |
CN107183696A (en) * | 2017-07-19 | 2017-09-22 | 北京加康生物技术有限公司 | A kind of health food and preparation method thereof |
CN108721628A (en) * | 2018-07-05 | 2018-11-02 | 河北东方韵健康管理股份有限公司 | A kind of formula and its preparation process of the complex peptides that can treat fatty liver |
CN109234344A (en) * | 2018-10-30 | 2019-01-18 | 吉林农业大学 | A kind of quinoa peptide and its preparation method and application |
CN109757734A (en) * | 2019-03-01 | 2019-05-17 | 上海傅克化学科技有限公司 | A kind of polypeptide oral liquor and preparation method thereof |
CN109770368A (en) * | 2019-04-02 | 2019-05-21 | 新疆正生营养研究院(有限公司) | A kind of more taste plant polypeptide weight losing meal-replacing powders and preparation method thereof |
-
2019
- 2019-11-29 CN CN201911197176.XA patent/CN111000249A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106912960A (en) * | 2017-03-06 | 2017-07-04 | 青岛海大华旗生物科技有限公司 | A kind of hypoglycemia healthcare food and preparation method thereof |
CN107183696A (en) * | 2017-07-19 | 2017-09-22 | 北京加康生物技术有限公司 | A kind of health food and preparation method thereof |
CN108721628A (en) * | 2018-07-05 | 2018-11-02 | 河北东方韵健康管理股份有限公司 | A kind of formula and its preparation process of the complex peptides that can treat fatty liver |
CN109234344A (en) * | 2018-10-30 | 2019-01-18 | 吉林农业大学 | A kind of quinoa peptide and its preparation method and application |
CN109757734A (en) * | 2019-03-01 | 2019-05-17 | 上海傅克化学科技有限公司 | A kind of polypeptide oral liquor and preparation method thereof |
CN109770368A (en) * | 2019-04-02 | 2019-05-21 | 新疆正生营养研究院(有限公司) | A kind of more taste plant polypeptide weight losing meal-replacing powders and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109452521B (en) | Auxiliary uric acid peptide reducing solid beverage, preparation method and application | |
CN102091315B (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
CN102145158A (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
CN1742927A (en) | Medicinal tablet made from fruit of Chinese wolfberry and spica Mori and its preparing process | |
CN1814167A (en) | Health-care for diabetes | |
CN109329930A (en) | A kind of composition and preparation method thereof for promoting uric acid to reduce | |
CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
CN111771988A (en) | Nutritional food suitable for diabetic patients and preparation method thereof | |
CN103285145A (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
CN1742971A (en) | Instant preparation of Fructus sea semen Amomi and hawthorn and preparing process | |
CN100431568C (en) | Chinese medicine for treating puerperal hypogalactia | |
CN102133385A (en) | Ginger and white pepper composition, preparation method thereof and application thereof to preparation of medicaments for attenuation and synergia in cancer radiochemotherapy | |
CN104382002A (en) | Maca tablet for alleviating fatigue | |
CN105031404A (en) | Traditional Chinese and western medicinal compound preparation for reducing weight and lowering lipid | |
CN109043555A (en) | A kind of Special food and preparation method thereof that hyperglycemic patients are edible | |
CN111000249A (en) | Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof | |
CN104825817B (en) | A kind of Chinese medicine preparation with antitumor action | |
CN109805235B (en) | Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof | |
CN103272147B (en) | Traditional Chinese medicine preparation for curing vomiting of pregnancy | |
CN112568430A (en) | A composition comprising semen Phaseoli vulgaris and fructus Momordicae Charantiae for reducing weight and fat, and its preparation method | |
CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
CN105902867B (en) | A herbal composition for reducing hypertension, hyperglycemia and hyperlipidemia, and its preparation method | |
CN101002804A (en) | Pure natural preparations used as depressor and hypolipidemic, and preparing method thereof | |
CN104013853B (en) | A kind of composition of strong kidney kidney tonifying and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |